Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 19 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 68% bullish and 31%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $150,092, and 15 are calls, for a total amount of $756,558.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $120.0 for Moderna during the past quarter.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Moderna's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Moderna's significant trades, within a strike price range of $40.0 to $120.0, over the past month.
Moderna Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | SWEEP | BULLISH | 09/19/25 | $4.25 | $4.1 | $4.25 | $95.00 | $135.0K | 548 | 319 |
| MRNA | CALL | SWEEP | BEARISH | 12/20/24 | $4.1 | $4.0 | $4.05 | $60.00 | $101.2K | 1.4K | 291 |
| MRNA | CALL | SWEEP | BULLISH | 11/15/24 | $4.05 | $4.0 | $4.0 | $55.00 | $83.6K | 856 | 351 |
| MRNA | PUT | SWEEP | BEARISH | 12/20/24 | $1.22 | $1.17 | $1.21 | $40.00 | $60.2K | 774 | 503 |
| MRNA | CALL | SWEEP | BULLISH | 09/19/25 | $4.2 | $4.05 | $4.2 | $95.00 | $60.0K | 548 | 463 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Moderna Standing Right Now?
- With a trading volume of 1,969,412, the price of MRNA is down by -1.22%, reaching $53.44.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 17 days from now.
What The Experts Say On Moderna
In the last month, 2 experts released ratings on this stock with an average target price of $55.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Bernstein downgraded its action to Market Perform with a price target of $55. * Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Moderna, targeting a price of $55.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
